数据日期 2026-10-29 · 生成时间 2026-10-29 06:03
研究问题
Pregnancy at advanced maternal age (over age 35) is among the leading causes of adverse maternal–perinatal outcomes and has become more prevalent worldwide in recent decades because of the advancement of modern societies.1–3 Delayed childbearing, changing educational and professional priorities, and broader access to assisted reproductive technologies have all contributed to a continuous increase in the proportion…
方法
The collection and use of human samples were approved by the Medical Science Research Ethics Committee of Peking University Third Hospital (Approval No.；Written informed consent was obtained from all participants prior to their inclusion in the study.；Clinical sample collection Endometrial samples were obtained from patients undergoing hysteroscopic examination at the Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, China.；The study population included a younger group of patients aged 22–32 years (n = 15) and an aging group aged 40–45 years (n = 19).
核心结论
(n = 3 independent biological replicates) *p < 0.05; p < 0.01; *p < 0.001 (Rb1, ginsenoside Rb1; Young, EnSCs in the young female group; Aging, EnSCs in the aging female group; Aging + Rb1, EnSCs in the aging female group treated with Rb1; ROS, reactive oxygen species) Ginsenoside Rb1 alleviates uterine aging via AMPK-mediated mTOR. . .；Data are shown as the means ± SDs (n = 3 independent biological replicates); *p < 0.05; p < 0.01; *p < 0.001 (Rb1, ginsenoside Rb1; Young, young murine uteri (n = 6); Aging, aging murine uteri (n = 6); Aging + Rb1, aging murine uteri treated with Rb1 (n = 6)) Ginsenoside Rb1 alleviates uterine aging via AMPK-mediated mTOR. . . ‖ 结论：These results indicate that stromal senescence and defective decidualization, together with epithelial dysfunction, constitute critical phenotypes of uterine aging.
局限
Although these results, together with those of previous reports, support the favorable safety profile of Rb1, we acknowledge that future studies should include long-term administration, comprehensive hematological and biochemical assessments, and pharmacokinetic profiling to fully establish the systemic safety of Rb1 for clinical application.；Future studies are needed to further elucidate the potential feedback loops between mTOR and NF-κB under distinct physiological and pathological conditions.
对本项目的价值
★★★★★ 营养感知与自噬轴决定"干预窗口 + 剂量方案"，是组合疗法的时间锚。顶刊证据；命中核心 mTOR/AMPK；最大样本量约 1,149；设计 单细胞、多组学。
全文来源
Nature OA PDF（正文 88,374 字符，已过标题/DOI 逐字归属校验）
原文题录
- 英文标题：Ginsenoside Rb1 alleviates uterine aging via AMPK-mediated mTOR inactivation.
- 期刊与标识：Signal Transduct Target Ther · PMID 42946698 · DOI 10.1038/s41392-026-02970-4**
A 级证据分级：A 级（同行评议人体研究）
本文属人体研究证据，但需注意：观察性或小样本干预的结论不等于已证实临床获益；效应量与长期安全性仍需更大规模、更长随访的试验验证。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。